Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease
- 1 December 2005
- journal article
- review article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 338 (2) , 687-693
- https://doi.org/10.1016/j.bbrc.2005.09.146
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionBiochemical and Biophysical Research Communications, 2005
- Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulationBritish Journal of Haematology, 2004
- Stromal Cell-Derived Factor-1 (SDF-1) Recruits Osteoclast Precursors by Inducing Chemotaxis, Matrix Metalloproteinase-9 (MMP-9) Activity, and Collagen TransmigrationJournal of Bone and Mineral Research, 2003
- Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone diseaseBritish Journal of Haematology, 2003
- Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myelomaInternational Journal of Cancer, 2003
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood, 2002
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and CytokinesBiochemical and Biophysical Research Communications, 1998
- Serum osteocalcin concentrations in patients with multiple myeloma — correlation with disease stage and survivalJournal of Internal Medicine, 1992